Status:
COMPLETED
Psychosocial Factors and Quality of Life in the Effect of Fear of COVID-19 With Cystic Fibrosis
Lead Sponsor:
Elif Kabasakal
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
16+ years
Brief Summary
The purpose of this study; The COVID-19 pandemic is to investigate the effects of COVID-19 fear levels of patients with cystic fibrosis on the psychosocial and quality of life levels of individuals.
Detailed Description
After individuals were informed about the study, it was administered to individuals who gave written informed consent.This study was carried out on individuals with cystic fibrosis and healthy individ...
Eligibility Criteria
Inclusion
- be 16 years of age or older
- Having been diagnosed with Cystic Fibrosis
- Volunteering to participate in the research
Exclusion
- Being mentally incapable of successfully applying the scales to be applied for evaluation purposes
- Being treated with sedative and antiepileptic drugs
- Pregnancy
Key Trial Info
Start Date :
November 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 25 2021
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT05195216
Start Date
November 20 2021
End Date
December 25 2021
Last Update
January 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Elif Kabasakal
Istanbul, İ̇stanbul, Turkey (Türkiye), 34734